22:30 , Jan 6, 2017 |  BC Week In Review  |  Clinical News

GAP3KO vaccine: Ph I data

An open-label, U.S. Phase I trial in 10 healthy volunteers showed that GAP3KO administered via the bite of 150-200 GAP3KO-infected mosquitoes under controlled conditions prevented malaria infection in all subjects. Specifically, all 10 subjects developed...
00:09 , Jan 5, 2017 |  BC Extra  |  Clinical News

Malaria vaccine shows promise in Phase Ia trial

In a study published Wednesday in Science Translational Medicine, researchers at the Center for Infectious Disease Research and Fred Hutchinson Cancer Research Center said a vaccine using genetically attenuated parasites prevented malaria infection in all...
07:00 , Mar 15, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Multiple myeloma (MM) Glycogen synthase kinase 3b (GSK3B); NF-kB; nuclear factor of k light polypeptide gene enhancer in...
08:00 , Jan 16, 2012 |  BioCentury  |  Emerging Company Profile

Rel-MD: Blocking two paths

Most inhibitors of NF-kappa B activation on the market and in development target only the better known of two pathways. Rel-MD Inc. thinks the lesser-known pathway actually plays a more important role in disease and...
07:00 , Aug 6, 2009 |  BC Innovations  |  Distillery Techniques

Technology: Drug platforms

Approach Summary Licensing status Publication and contact information Drug platforms Live attenuated Plasmodium falciparum vaccine to prevent malaria infection ...
07:00 , Aug 6, 2009 |  BC Innovations  |  Cover Story

A double knockout against malaria

Developing subunit vaccines against Plasmodium falciparum is difficult because the malaria parasite expresses many different antigens over the course of its life cycle. American and Australian researchers have now designed a genetically attenuated P. falciparum...